Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth
Research Triangle Park, NC and Cambridge, UK, September 12, 2018 -- Inivata, a leader in liquid biopsy, today announces the strengthening of its senior leadership team with the appointment of Clive Morris, formerly Chief Medical Officer, as Chief Executive Officer, Stacy Chick as Chief Commercial Officer and Thomas Schlumpberger as VP Business Development.
Clive Morris joined Inivata in May 2016 as Chief Medical Officer. Previously, he worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ. He has extensive experience across all phases of life-science product development and commercialization including numerous marketed oncology products. Clive is also a non-executive director of Wheatsheaf investments and the InnovateUK Medicines Discovery Catapult and is accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians.
Chairman of Inivata, Jeffrey H. Buchalter, said: “Since joining Inivata, Clive has played a key role in the development and validation of our InVision liquid biopsy platform into a powerful tool to aid physicians in their treatment decisions for lung cancer patients. As CEO, his deep experience in the global life-science industry, translational and clinical medicine will be invaluable in the next stage of the company’s growth.”
Stacy Chick brings over 25 years of US healthcare commercial experience to Inivata. Joining the team as a consultant in early 2018, Stacy quickly leveraged her commercial sales, marketing, market access and operations experience to accelerate the launch planning for InVisionFirst™-Lung. Based on these contributions, Stacy was appointed Chief Commercial Officer effective September 1, 2018. Prior to joining Inivata, Stacy held executive-level sales, marketing and market access leadership roles in public and privately-held life science companies including Bristol-Myers Squibb, Sanofi, UCB, Mallinckrodt and Archimedes Pharma. Stacy is a member of the International Association for the Study of Lung Cancer (IASLC), WBL and the Leukemia and Lymphoma Society.
Dr Thomas Schlumpberger previously held a leadership position at Singulex as their Head of Diagnostic Business & Vice President Diagnostics and has 15+ years’ experience in the IVD, life science and pharmaceutical industries. In his role as VP of Corporate Development and Alliance Management, he was charged with capturing growth opportunities outside of clinical diagnostics. Additionally, he led all collaborations and agreements necessary to grow and operate the Singulex CLIA laboratory and the Singulex diagnostic business. He previously held a key role within business development at Annai Systems and AliveCor and served as the Chief Commercial Officer at Invitae (f/k/a Locus Development), and as Senior VP of International Sales and Business Development at Epocal. Before joining the healthcare industry, Thomas served as a Consultant at McKinsey & Company. He currently sits on the board of DxEconomics and serves as Deal Advisor to CroMedX, both in Toronto, ON.
Clive Morris, Chief Executive Officer of Inivata, said: “I am delighted to take on the leadership of Inivata at this exciting time. Our InVision ctDNA assay has the potential to transform how patients with cancer are managed, and I look forward to guiding the company through the next stage of our growth. Stacy brings valuable commercial experience as we prepare our commercial launch plans, and along with Thomas leading our business development, we are primed to make the transition from a research- based company to a fully integrated organization spanning R&D through to commercialization.”
Ends
About Inivata
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst™-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Media Contacts:
Consilium Strategic Communications
Chris Gardner/Laura Thornton/Sarah Wilson
inivata@consilium-comms.com +44 (0)20 3709 5700
Karen Chandler-Smith
karen.chandler-smith@inivata.com +44 (0)7900 430235